BridgeBio Pharma (BBIO) Shares Outstanding (Diluted Average) (2020 - 2026)

BridgeBio Pharma has disclosed Shares Outstanding (Diluted Average) across 7 years of filings, most recently posting $194.8 million for Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $194.8 million, up 2.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $194.8 million (up 2.44% YoY), and the FY2025 annual result was $191.5 million, up 2.93% from the prior year.
• Shares Outstanding (Diluted Average) came in at $194.8 million for Q1 2026 at BridgeBio Pharma, up from $191.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $194.8 million in Q1 2026 to a low of $145.9 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $178.7 million (2024), against an average of $171.7 million.
• Across the five-year window, Shares Outstanding (Diluted Average) climbed 2.16% in 2022 and rose 17.07% in 2024, its largest moves.
• BridgeBio Pharma's Shares Outstanding (Diluted Average) stood at $147.5 million in 2022, then gained by 10.39% to $162.8 million in 2023, then gained by 14.3% to $186.1 million in 2024, then increased by 2.93% to $191.5 million in 2025, then gained by 1.7% to $194.8 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $194.8 million (Q1 2026), $191.5 million (Q4 2025), and $191.9 million (Q3 2025), per Business Quant data.